hznp
http://ih.advfn.com/p.php?pid=nmona&article=72658003&adw=1126416
As previously announced in our Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on September 12, 2016, we entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Misneach Corporation, a Delaware corporation and our indirect wholly owned subsidiary (“Purchaser”), and Raptor Pharmaceutical Corp., a Delaware corporation (“Raptor”). On September 26, 2016, pursuant to the terms of the Merger Agreement, Purchaser commenced a tender offer to purchase all of the issued and outstanding shares of Raptor common stock for $9.00 per share in cash (the “Offer”). If successful, the Offer will be followed by a merger of Purchaser with and into Raptor, with Raptor surviving as our indirect wholly owned subsidiary (together with the Offer, the “Transactions”).
http://ih.advfn.com/p.php?pid=nmona&article=72657748&adw=1126416
Horizon Pharma plc (Nasdaq:HZNP) (“Horizon”), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that Horizon Pharma, Inc. and Horizon Pharma USA, Inc., its wholly owned subsidiaries, intend, subject to market and other considerations, to offer $300 million aggregate principal amount of senior notes due 2024, and to borrow $375 million aggregate principal amount of incremental term loans under Horizon’s existing senior secured credit facility.
Horizon currently expects to use the net proceeds from the offering of notes and the incremental term loans to fund a portion of Horizon’s planned acquisition of Raptor Pharmaceutical Corp. (“Raptor”), repay Raptor’s outstanding debt, and pay any prepayment premiums, fees and expenses in connection with the foregoing.